A substantial discordance in ER and HER2 status between primary and metastatic tumor tissue has been reported [53-55], and a study has demonstrated differences in the immunoreactivity of TIMP-1 in primary breast tumor tissue and the corresponding axillary lymph node metastasis [56]. This evidence concerns the gene ERBB2 and metastatic neoplasm.